Subject(s)
Mitochondrial Encephalomyopathies/complications , Mitochondrial Proton-Translocating ATPases/genetics , Myoclonic Epilepsies, Progressive/genetics , DNA, Mitochondrial/genetics , Electroencephalography , Electroretinography , Female , Gait Ataxia/etiology , Humans , Middle Aged , Mitochondrial Encephalomyopathies/classification , Mitochondrial Encephalomyopathies/genetics , Mutation, Missense , Organ Specificity , Phenotype , Photic Stimulation , Point MutationABSTRACT
After bone marrow transplantation in children, it is essential to detect secondary liver diseases and hepatotoxic effects of immunosuppressive therapy. These can be revealed by cytolytic syndromes sometimes associated with cholestasis. It is therefore important to find an early and specific cholestasis enzymatic marker. A retrospective study of the changes in levels of biological parameters has been carried out in 13 children who underwent one or more bone marrow transplantations. During the 3 months following bone marrow transplantation, all patients developed liver injury characterized by an early and very elevated 5'-nucleotidase activity (sometimes more than 40 times the upper reference limit), a moderate increase in alkaline phosphatase activity, a variable increase in alanine aminotransferase activity and inconstant changes in total bilirubin levels. These results show that cytolytic syndrome and cholestasis are often associated with increases in 5'-nucleotidase and alkaline phosphatase activities. These increases are not correlated, probably due to the influence of therapy on the synthesis and release of both enzymes in the liver. 5'-nucleotidase seems to be the best marker for the detection and follow-up of liver disease in this patient group.
Subject(s)
5'-Nucleotidase/blood , Alkaline Phosphatase/blood , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Transplantation/adverse effects , Leukemia/therapy , Adolescent , Alanine Transaminase/blood , Bilirubin/blood , Child , Child, Preschool , Female , Humans , Leukemia/blood , Leukemia/drug therapy , Liver Diseases/blood , Liver Diseases/etiology , Male , Postoperative PeriodABSTRACT
In order to predict better thrombo-embolic complications that sometimes occur after delivery, we studied the variations of antithrombin III levels (A.T. III) in 703 women, at the 8th month pregnancy (275 levels), on the first day (609 levels) and the 5th day (516 levels) after delivery. The average antithrombin III levels were respectively 90.8%, 83.4% and 98.7%. We found 120 levels (8.5%) lower than 80% (normal range for A.T. III = 80-120%), 107 of which on the first day after delivery were followed by a rapid increase to the normal range; these women however were satisfactory in the post-partum period. Therefore predicting thrombo-embolic complications in the post-partum period through A.T. III levels determination would seem to be pointless.
